Global Multiple Endocrine Neoplasia Treatment Market, By Type (Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2), Therapy Type (Hormonal Therapy, Chemotherapy, Radiation Therapy), Treatment Type (Medication, Surgery), Drugs (Somatostatin Analogues, Thyrosin Kinase Receptors Inhibitor, mTOR Inhibitor, and Others), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) – Industry Trends and Forecast to 2030.
Multiple Endocrine Neoplasia Treatment Market Analysis and Size
Multiple endocrine neoplasia type 1 affects around 1 in 30,000 people. The onset of multiple endocrine neoplasia (MEN) type 1 can vary greatly. It has been diagnosed in children aged 8 years and adults as old as 80. It has been witnessed that the parathyroid glands are the most commonly affected endocrine glands in multiple endocrine neoplasia type 1. An increase in the huge financial support to the scientists for emerging novel interventions will increase the market growth. Over the years, it has been observed that there is currently no cure for multiple endocrine neoplasias, but it is manageable.
Data Bridge Market Research analyses that the multiple endocrine neoplasia treatment market, which was USD 2.79 billion in 2022, would rise to USD 6 billion by 2030 and is expected to undergo a CAGR of 10% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Multiple Endocrine Neoplasia Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2), Therapy Type (Hormonal Therapy, Chemotherapy, Radiation Therapy), Treatment Type (Medication, Surgery), Drugs (Somatostatin Analogues, Thyrosin Kinase Receptors Inhibitor, mTOR Inhibitor and Others), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
|
|
Countries Covered
|
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer, Inc (U.S.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), Ipsen Pharma (France), Bristol-Myers Squibb Company (U.S.), Amgen Inc. (U.S.), GSK Plc (U.K.), Regeneron Pharmaceuticals Inc (U.S.), Mylan N.V. (U.S.), Sanofi (France), Lilly (U.S.) and AbbVie Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Multiple endocrine neoplasias are a group of rare, inherited disorders that affect endocrine glands and develop noncancerous or cancerous tumors in at least two endocrine glands. Numerous types of tumors are related to multiple endocrine neoplasias. Many of the tumors associated with MEN type 1 are benign (noncancerous), but few can be cancerous (malignant) and can spread to other areas of your body.
Global Multiple Endocrine Neoplasia Treatment Market Dynamics
Drivers
- Increasing Incidence of Multiple Endocrine Neoplasia
Multiple endocrine neoplasia type 1 affects around 1 in 30,000 people. Multiple endocrine neoplasia type 2 affects around 1 in 35,000 people. Among the subtypes of type 2, type 2A is the most prevalent form, which FMTC follows. Type 2B is relatively uncommon, resulting in around 5 percent of all cases of type 2. The incidence of multiple endocrine neoplasia type 4 is unknown, though the condition appears rare. This increasing prevalence resulted in the increasing demand for its treatment types. This factor leads to the growth of the market.
- Growing Diagnostic Procedures of Multiple Endocrine Neoplasia
There are varied diagnostic procedures that lead to market growth. Procedures such as magnetic resonance imaging (MRI), computerized tomography (C.T.) scans, and genetic testing are used widely for the correct diagnosis of patients. A genetic test must be performed to detect on a molecular level if the child has MEN2. Thus, this factor help in the market growth.
Opportunities
- Increasing Treatment Options for Multiple Endocrine Neoplasia
Several treatment options lead to market growth. Therapeutics to treat symptoms and combat excess hormone effects surge the market growth. Surgery is often performed to remove tumors or entire affected glands, such as the thyroid. Chemotherapy and radiation therapy are also performed to improve the patient's condition. Thus, this factor boosts market growth.
Restraints/Challenges
- Side-Effects of Multiple Endocrine Neoplasia Treatment
Numerous effects are associated with multiple endocrine neoplasia treatment products. Local effects include diarrhea, acid reflux (esophageal reflux), abdominal pain, and peptic ulcers. Other symptoms include bone pain, broken bones, tiredness, kidney stones, and ulcers in the stomach or intestines. Thus, this factor impedes market growth.
This multiple endocrine neoplasia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the multiple endocrine neoplasia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Multiple Endocrine Neoplasia Treatment Market Scope
The multiple endocrine neoplasia treatment market is segmented on the basis of indication, technology, product type, route of administration, end users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Multiple Endocrine Neoplasia Type 1
- Multiple Endocrine Neoplasia Type 2
Therapy Type
- Hormonal Therapy
- Chemotherapy
- Radiation Therapy
Treatment Type
- Medication
- Surgery
Drugs
- Somatostatin Analogues
- Thyrosin Kinase Receptors Inhibitor
- mTOR Inhibitor
- Others
Route of Administration
- Oral
- Injectable
End User
- Hospitals
- Homecare
- Specialty Clinic
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
Multiple Endocrine Neoplasia Treatment Market Regional Analysis/Insights
The multiple endocrine neoplasia treatment market is analyzed and market size insights and trends are provided by indication, technology, product type, route of administration, end users and distribution channel as referenced above.
The countries covered in the multiple endocrine neoplasia treatment market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market in the forecast period because of the increased demand for disease-specific novel treatment. Also, the rise in the incidence of endocrine tumors in this region is boosting the market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The multiple endocrine neoplasia treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for multiple endocrine neoplasia treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the multiple endocrine neoplasia treatment market. The data is available for historic period 2011-2021.
Competitive Landscape and Multiple Endocrine Neoplasia Treatment Market Share Analysis
The multiple endocrine neoplasia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to multiple endocrine neoplasia treatment market.
Some of the major players operating in the multiple endocrine neoplasia treatment market are:
- Pfizer, Inc (U.S.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Ipsen Pharma (France)
- Bristol-Myers Squibb Company (U.S.)
- Amgen Inc. (U.S.)
- GSK Plc (U.K.)
- Regeneron Pharmaceuticals Inc (U.S.)
- Mylan N.V. (U.S.)
- Sanofi (France)
- Lilly (U.S.)
- AbbVie Inc. (U.S.)
SKU-